Untitled-1.png
  • black-back-closed-envelope-shape
  • White Instagram Icon
  • White Facebook Icon
  • White LinkedIn Icon

Copyright ©2019 by Sanomics Limited. All rights reserved.

PD-L1 IHC 22C3 pharmDx is a qualitative immunohistochemical assay using Monoclonal Mouse Anti-PD-L1, Clone 22C3 to detect PD-L1 protein in FFPE tissue specimens using EnVision FLEX visualization system on Autostainer Link 48. It detects PD-L1 expression with a dynamic range of tumor-positive (TPS) 0-100% and combined positive score (CPS) 0-10+.

 

Cancers include lung cancer, gastric cancer, urothelial cancer, cervical cancer etc.

 

Sample types: FFPE Block or 5 x 4μm unstained FFPE slides

 

Turnaround time: 8 working days upon sample arrival

Why use PD-L1 IHC 22C3?

Cost effectiveness

Immuno-Oncology(IO) treatment could be considered.

Why does PD-L1 matter?

In normal circumstance, our T cells can detect cancer cells and activate the body’s defense mechanism to attack the cancer cells. However, some tumor cells can mimic normal cells by upregulating the expression of PD-L1 as a mechanism to evade the body natural response. As a result, T cells will stop attacking the cancer cells.

 

The purpose of our test is to evaluate the proportion of PD-L1 positive cells.

-Because clinical studies have proven that certain proportion of

 PD-L1 leads to improved clinical outcomes in response to IO therapies.

cell.png